Ainos (NASDAQ:AIMD) Releases Quarterly Earnings Results

Ainos (NASDAQ:AIMD) issued its earnings results on Monday. The company reported ($0.76) earnings per share for the quarter, FiscalAI reports.

Ainos Stock Down 2.9%

NASDAQ AIMD traded down $0.04 during trading hours on Monday, hitting $1.35. The company’s stock had a trading volume of 18,720 shares, compared to its average volume of 660,542. The company has a market capitalization of $6.50 million, a PE ratio of -0.34 and a beta of 2.39. The company has a current ratio of 2.96, a quick ratio of 2.67 and a debt-to-equity ratio of 1.10. Ainos has a 52 week low of $1.26 and a 52 week high of $4.50. The company’s 50-day simple moving average is $1.65 and its two-hundred day simple moving average is $2.38.

Insider Buying and Selling

In other news, major shareholder Carbon Nano Technology Taiwan sold 46,000 shares of the company’s stock in a transaction on Wednesday, January 28th. The shares were sold at an average price of $2.17, for a total value of $99,820.00. Following the completion of the sale, the insider owned 989,925 shares in the company, valued at $2,148,137.25. This represents a 4.44% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last three months, insiders sold 47,281 shares of company stock worth $102,152. Insiders own 9.79% of the company’s stock.

Institutional Trading of Ainos

A number of large investors have recently added to or reduced their stakes in AIMD. Mariner LLC bought a new stake in shares of Ainos in the fourth quarter valued at approximately $37,000. Two Sigma Investments LP bought a new position in Ainos in the 3rd quarter worth approximately $80,000. DRW Securities LLC boosted its holdings in Ainos by 272.6% in the 4th quarter. DRW Securities LLC now owns 66,211 shares of the company’s stock worth $109,000 after buying an additional 48,439 shares during the period. Finally, Renaissance Technologies LLC grew its stake in Ainos by 13.1% in the 4th quarter. Renaissance Technologies LLC now owns 66,300 shares of the company’s stock valued at $109,000 after buying an additional 7,700 shares in the last quarter.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Ainos in a research report on Monday, December 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock presently has a consensus rating of “Sell”.

Ainos Company Profile

Ainos, Inc (NASDAQ: AIMD) is a clinical‐stage biopharmaceutical company dedicated to developing inhalation therapies for patients with chronic pulmonary disorders. The company’s proprietary platform centers on a dry powder inhalation technology designed to deliver therapeutic agents directly to the lungs, potentially improving drug distribution and reducing systemic side effects compared to traditional oral or intravenous formulations.

The lead product candidate, AI‐401, is an inhaled formulation of ibuprofen in a dry powder format.